Drugs / FZ008-145
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06685809 | Nov 2024 → Apr 2026 | — | Guangzhou Fermion Technology Co., LTD | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FZ008-145 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06685809 ↗ |
| Route | Oral | “All participants will receive single dose of oral FZ008-145 solution or placebo.” NCT06685809 ↗ |